Methods for reducing the foreign body reaction

• US 20060002969A1
• Filed: 01/26/2005
• Published: 01/05/2006
• Est. Priority Date: 01/27/2004
• Status: Abandoned Application

• Current Assignee: University of Washington
• Original Assignee: University of Washington
• Inventors: Kyriakides, Themis, Bornstein, Paul
• Application Number:
  US11/044,640
• Publication Number:
  US 20060002969A1
• Time in Patent Office: Days
• US Class Current: 424/423
• CPC Class Codes: A61K 39/44 Antibodies bound to carriers
• CPC Class Codes: C07K 16/40 against enzymes

Abstract

The present invention provides methods for reducing the foreign body reaction against a structure implanted within an animal body. The methods include the step of providing an amount of an MMP-9 antagonist at the site of the implanted structure that is sufficient to reduce the foreign body response against the structure. The invention also provides implantable medical devices that include a surface layer that includes an amount of an MMP-9 antagonist sufficient to reduce the foreign body response against the device.

Claims

1. An implantable medical device comprising:

(a) a device body; and

(b) a surface layer attached to the device body, the surface layer comprising an amount of an MMP-9 antagonist sufficient to reduce the foreign body response against the device, wherein the device is adapted to be completely or partially implanted within an animal.

2. An implantable medical device of claim 1 wherein the implantable medical device is selected from the group consisting of a vascular graft, a stent, an artificial blood vessel, an artificial lens, an artificial bone joint, a biosensor, a catheter, and artificial skin.

3. An implantable medical device of claim 1 wherein the layer completely covers the body of the device.

4. An implantable medical device of claim 1 wherein the layer partially covers the body of the device.

5. An implantable medical device of claim 1 wherein the MMP-9 antagonist is selected from the group consisting of antisense MMP-9 nucleic acid molecules, anti-MMP-9 antibodies, anti-MMP-9 siRNA molecules and non-nucleic acid antagonists of MMP-9.

6. An implantable medical device of claim 1 wherein the surface layer comprises a porous matrix and a member of the group consisting of antisense MMP-9 nucleic acid molecules, anti-MMP-9 antibodies, anti-MMP-9 siRNA molecules and non-nucleic acid antagonists of MMP-9 is releasably disposed within the porous matrix.

7. An implantable medical device of claim 1 wherein a member of the group consisting of antisense MMP-9 nucleic acid molecules, anti-MMP-9 antibodies, anti-MMP-9 siRNA molecules and non-nucleic acid antagonists of MMP-9 is covalently attached to the device body.

8. A method of reducing the foreign body reaction against a structure implanted within an animal body, the method comprising the step of providing an amount of an MMP-9 antagonist, at the site of the implanted structure, that is sufficient to reduce the foreign body response against the structure.

9. A method of claim 8 wherein the structure is an implantable medical device adapted to be affixed to, or implanted within, the soft tissue of an animal.

10. A method of claim 9 wherein the implantable medical device is selected from the group consisting of a vascular graft, a stent, an artificial blood vessel, an artificial lens, an artificial bone joint, a biosensor, a catheter, and artificial skin.

11. A method of claim 8 wherein the MMP-9 antagonist is selected from the group consisting of antisense MMP-9 nucleic acid molecules, anti-MMP-9 antibodies, anti-MMP-9 siRNA molecules and non-nucleic acid antagonists of MMP-9.

12. A method of claim 8 wherein the MMP-9 antagonist is non-covalently attached to an external surface of the structure.

13. A method of claim 8 wherein the MMP-9 antagonist is covalently attached to an external surface of the structure.

14. A method of claim 8 wherein the MMP-9 antagonist is releasably disposed within a porous matrix attached to an external surface of the structure.

15. A method of claim 8 wherein the MMP-9 antagonist is releasably disposed within a gel attached to an external surface of the structure.

16. A method of claim 8 wherein the MMP-9 antagonist is injected into a region of the body surrounding the implanted structure.

17. A method of claim 8 wherein the body is a human body.